Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future
Approximately 8-42% of premature infants with chronic lung disease of prematurity, bronchopulmonary dysplasia (BPD), develop pulmonary hypertension (PH). Infants with BPD-PH carry alarmingly high mortality rates of up to 47%. Effective PH-targeted pharmacotherapies are desperately needed for these i...
Saved in:
Main Authors: | Candice D. Fike (Author), Judy L. Aschner (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pulmonary hypertension in infants with bronchopulmonary dysplasia
by: Gi Beom Kim
Published: (2010) -
Predictive analytics in bronchopulmonary dysplasia: past, present, and future
by: Bryan G. McOmber, et al.
Published: (2024) -
Efficacy of Sildenafil in Infants with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension
by: Kacie Dillon, et al.
Published: (2023) -
Novel Strategies to Reduce Pulmonary Hypertension in Infants With Bronchopulmonary Dysplasia
by: Ahmed El-Saie, et al.
Published: (2020) -
Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?
by: Rishika P. Sakaria, et al.
Published: (2022)